RxDoctor Payments Data

Richard Squires, MD

Pulmonary Disease · Takoma Park, MDNPI 1861485047

Payments from drug & device makers

$1,420in general payments, 2019–2025

Across 75 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$591
  • AstraZeneca$386
  • Mylan Specialty L.p.$105
  • Mallinckrodt Hospital Products Inc.$70
  • Electromed, Inc.$62
  • Mallinckrodt Enterprises LLC$46
  • plus $160 from 7 others

What the payments were for

  • Food & beverage$1,420100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,420 in reported general payments places this provider in the 50th percentile of 297 pulmonary disease providers in Maryland.

See all pulmonary disease providers in Maryland

Medicare billing

Part B allowed, 2024
$127,762
Medicare patients
269
Services billed
1,339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter384$365,077
Breztri AerosphereBudesonide/Glycopyr/Formoterol97$96,040
Breo ElliptaFluticasone/Vilanterol67$38,395
Ambrisentan11$31,158
SymbicortBudesonide/Formoterol Fumarate101$29,461
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr53$28,541
Spiriva HandihalerTiotropium Bromide38$24,687
Spiriva RespimatTiotropium Bromide21$15,060
EliquisApixaban18$12,390
DuleraMometasone/Formoterol19$10,831
Albuterol Sulfate HfaAlbuterol Sulfate472$10,527
XareltoRivaroxaban13$10,141
Arnuity ElliptaFluticasone Furoate37$9,459
Azelastine-FluticasoneAzelastine/Fluticasone53$6,014
Azelastine Hcl96$5,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$591$441,472541 claims
AstraZenecaBreztri Aerosphere, Symbicort$386$125,501198 claims
Boehringer IngelheimSpiriva Respimat$11$15,06021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 297 pulmonary disease providers in Maryland.

Other pulmonary disease in Takoma Park

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →